About the dataset

Primary description: Alzheimer’s biomarkers and progression

The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a public–private partnership coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. Since its launch in 2003 under the leadership of Principal Investigator Michael W. Weiner, MD, 63 sites across the United States and Canada have contributed to the ongoing effort to identify, track, and understand Alzheimer’s disease (AD) and its early stages. The study collects longitudinal multimodal data, including structural and functional MRI, positron emission tomography (PET) with FDG, PiB, and AV-45 tracers, biological samples (blood, urine, and cerebrospinal fluid in a subset), and comprehensive clinical and neuropsychological assessments from over 1,000 participants with AD, mild cognitive impairment (MCI), or age-matched controls.

Study Alzheimer’s Disease Neuroimaging Initiative
Study Website ADNI
Data Descriptor Paper https://pmc.ncbi.nlm.nih.gov/articles/PMC2809036/
DUA https://adni.loni.usc.edu/wp-content/themes/adni_2023/documents/ADNI_Data_Use_Agreement.pdf
Country/Region USA/Canada
Disease Tag alzheimers
Age (mean ± SD)
(Baseline) 		73.1 ± 7.3
Age Range
(Baseline) 		55-90
% Female 47.7
CUBIC Project /cbica/projects/ADNI
PI for CUBIC Access Approval Christos Davatzikos
N Subjects 2517
N MR Sessions 10913
Diagnoses
AD
Value V01 V02 V03 V04 V05 V06 V07 V08 V09 V10 V11 V12 V13 V14 V15 V16 V17
MCI 1103 904 757 632 481 329 205 148 108 70 37 25 10 5 2
CN 874 650 494 431 370 291 211 155 95 55 44 26 14 8 3 1 1
AD 422 362 352 329 239 171 128 88 68 42 31 16 12 4 1
nan 45 1 1 1 1 1
Hypertension
Value V01 V02 V03 V04 V05 V06 V07 V08 V09 V10 V11 V12 V13 V14 V15 V16 V17
Stage2 1366 683 565 501 391 271 209 135 96 50 41 26 14 3 2
Normal 646 715 618 511 395 293 199 144 100 63 43 25 16 7 3 1
Stage1 408 518 417 379 302 216 134 111 72 53 27 16 6 7 1 1
nan 24 1 3 1 3 12 3 2 3 1 1
Diabetes
Value V01 V02 V03 V04 V05 V06 V07 V08 V09 V10 V11 V12 V13 V14 V15 V16 V17
nan 1548 912 434 379 728 640 471 354 258 162 112 67 36 17 6 1 1
Normal 545 611 722 630 227 91 46 28 11 4
Prediabetic 243 275 333 298 95 40 18 7 2 1
Diabetic 108 119 114 85 41 21 10 3
Depression
Value V01 V02 V03 V04 V05 V06 V07 V08 V09 V10 V11 V12 V13 V14 V15 V16 V17
nan 2393 1855 1382 1192 985 703 483 342 232 145 93 59 33 16 5 1 1
Negative/absent 49 52 192 181 93 82 56 45 37 20 16 7 3 1 1
Positive/present 2 10 29 19 13 7 6 5 2 2 3 1
DLMUSE (v1.0.7)
(10858/10858 complete)
/cbica/projects/ADNI/Pipelines/ADNI_DLMUSE_2025/Results/DLMUSE_Volumes.csv
RAVENS (DRAMMS-1.4.1)
(10853/10858 complete)
/cbica/projects/ADNI/Pipelines/ADNI_3.5D_2020/Protocols/RAVENS
DLWMLS (v0.1.0)
(6075/10913 complete)
/cbica/projects/ADNI/Pipelines/ADNI_DLWMLS_2025/Results/ADNI_DLWMLS_DLMUSE_Segmented_Volumes.csv
Non-Imaging Data
/cbica/projects/ISTAGING/Pipelines/ClinicalDataConsolidation_201911/Data/External_Data/ADNI

Raw data downloaded from source.

https://adni.loni.usc.edu/data-samples/data-dictionary-search/

Data dictionary of raw data downloaded from source.

/cbica/projects/ISTAGING/Pipelines/ISTAGING_Data_Consolidation_2020/v2.0/istaging.csv

Data consolidated and harmonized in 2020.

This study: subset with df[df.Study == 'ADNI']

README: /cbica/projects/ISTAGING/Pipelines/ISTAGING_Data_Consolidation_2020/v2.0/README.md

Release Notes: /cbica/projects/ISTAGING/Pipelines/ISTAGING_Data_Consolidation_2020/v2.0/Release_Notes.md

Coming Soon

Data consolidated and harmonized in 2026.

This study: subset with df[df.Study == 'ADNI']

README: Coming Soon

Release Notes: Coming Soon


Funding
ADNI (National Institutes of Health Grant U01 AG024904, U01 AG072177) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012) are funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. MESA is supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences (NCATS). Brain MRI is supported by grant R01 HL127659 from the National Heart, Lung, and Blood Institute with additional support from the National Institute on Aging and grant R01 AG080821.